Immunocore (IMCR) announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous ...

Longer times from symptom onset to randomization equaled a smaller—or perhaps no—advantage for Impella vs standard care.

Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant ...

Patients with advanced or recurrent endometrial cancer derived a survival benefit from Jemperli plus chemotherapy. Treatment with the immunotherapy agent, Jemperli (dostarlimab), plus chemotherapy ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 June 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...